Mycophenolic acid trough level monitoring: Relevance in acute and chronic graft versus host disease and its relation with albumin

Clinical Transplantation

Volumn 25, Issue 2, 2011, Pages 222-227

  Hiwarkar, P ^a   Shaw, B E ^a,b   Tredger, J M ^c   Brown, N W ^c   Kulkarni, S ^a   Saso, R ^a   Evans, S ^a   Treleaven, J ^a   Davies, F E ^a   Ethell, M E ^a   Morgan, G J ^a   Potter, M N ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Graft versus host disease (GvHD); Mycophenolate mofetil; Mycophenolic acid levels; Serum albumin

Indexed keywords

ACICLOVIR; ALBUMIN; ALEMTUZUMAB; CYCLOSPORIN A; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACINETOBACTER INFECTION; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; BURKHOLDERIA CEPACIA INFECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; MALE; OPPORTUNISTIC INFECTION; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; PROTEUS INFECTION; PSEUDOMONAS INFECTION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIREMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; ALBUMINS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CHRONIC DISEASE; DRUG MONITORING; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953301752     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01226.x     Document Type: Article

References (20)

1. Kim JG, Sohn SK, Kim DH et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004: 73: 56.
2. Basara N, Blau WI, Römer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998: 22: 61.
3. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002: 30: 287.
4. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003: 25: 137.
5. Tredger JM, Brown NW, Adams J et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004: 10: 492.
6. Le Meur Y, Buchler M, Theierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007: 7: 2496.
7. Borrows R, Chusney G, Loucaidou M et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006: 6: 121.
8. Jacobson P, Rogosheske J, Barker JN et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005: 78: 486.
9. Tsaroucha AK, Zucker K, Esquenazi V, De Faria L, Miller J, Tzakis AG. Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapy. Transpl Immunol 2000: 8: 143.
10. Kiehl MG, Shipkova M, Basara N et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem 2000: 33: 203.
11. Jenke A, Renner U, Richter M et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001: 15: 176.
12. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998: 9: 1511.
13. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998: 34: 429.
14. Atcheson BA, Taylor PJ, Kirkpatrick CM et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004: 26: 284.
15. Shaw LM, Korecka M, Aradhye S et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000: 40: 624.
16. Prémaud A, Rousseau A, Le Meur Y, Lachâtre G, Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004: 26: 609.
17. Huang J, Jacobson P, Brundage R. Prediction of unbound mycophenolic acid concentrations in patients after heamatopoietic cell transplantation. Ther Drug Monit 2007: 29: 385.
18. Van Hest RM, Doorduijn JK, De Winter BC et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 2007: 29: 353.
19. Kiehl MG, Schäfer-Eckart K, Kröger M et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002: 34: 2922.
20. Lopez F, Parker P, Nademanee A et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005: 11: 307.